IP Library Granted Patent US 10,850,004
Granted Patent B2
US 10,850,004 · App. 15/555,245 · Granted Dec 1, 2020

Nerve cap and production thereof

Inventors: Pieter van den Berg (Groningen, NL); Hans Wicher Kuijper (Groningen, NL); Leendert Willem Schwab (Groningen, NL); Mariëtta Johanna Olga Elizabeth Bertleff (Groningen, NL); Harmen Hendrikus de Vries (Groningen, NL)
Assignee: Polyganics IP B.V.
A61L27/18A61B90/08A61L27/3878A61L27/58A61B2090/0815
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,850,004
App. No.
15/555,245
Granted
Dec 1, 2020
Kind
B2
Abstract

The invention is directed to a nerve cap for covering a nerve stump, comprising a tubular body with a closed end and an open end and essentially consisting of biodegradable polymeric material to prevent or treat symptoms caused by neuroma. The polymeric material preferably comprises a poly(DL-lactide-co-ε-caprolactone) copolymer obtained by the copolymerizaton of DL-lactide and ε-caprolactone, which copolymer has a lactide content of 51-75 mol %.

Claims (13)

1. A nerve cap for covering a nerve stump, comprising a tubular body with a closed end and an open end and comprising biodegradable polymeric material, which cap has at least one tab comprising one or more holes, wherein said at least one tab is located at the closed end of the tubular body of the nerve cap, wherein the biodegradable polymeric material comprises a poly(DL-lactide-co-ε-caprolactone) copolymer having a lactide content of 51-75 mol %.

2. The nerve cap according to claim 1 , wherein the at least one tab has a modulus of between 5 to 50 MPa, a toughness of between 0.5 and 2 J and/or a stress at present point of between 0.5 and 2 MPa.

3. The nerve cap according to claim 1 , wherein the fraction of the D-enantiomer or L-enantiomer of the lactide is from 65 mol % to 95 mol %.

4. The nerve cap according to claim 1 , wherein the copolymer has a lactide content of 55-70 mol %.

5. The nerve cap according to claim 4 , wherein the fraction of the D-enantiomer or L-enantiomer of the lactide in the polymeric material is from 65 mol % to 95 mol %.

6. The nerve cap according to claim 1 , wherein the polymeric material has a polydispersity (Mw/Mn) of less than 1.8.

7. The nerve cap according to claim 1 , wherein the polymeric material has an intrinsic viscosity of more than 4 dL/g.

8. The nerve cap according to claim 1 , wherein the at least one tab has a modulus of between 10 to 30 MPa.

9. The nerve cap according to claim 1 , wherein the fraction of the D-enantiomer or L-enantiomer of the lactide is from 70 mol % to 90 mol %.

10. The nerve cap according to claim 1 , wherein the polymeric material has a polydispersity (Mw/Mn) of less than 1.5.

11. The nerve cap according to claim 1 , wherein the polymeric material has an intrinsic viscosity of more than 5 dL/g.

12. The nerve cap according to claim 1 , wherein the nerve cap is configured to be immobilized in tissue by suture.

13. A method of treating and/or preventing symptoms caused by neuroma comprising capping said neuroma with the nerve cap according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2017
From: VAN DEN BERG, PIETER; KUIJPER, HANS WICHER; SCHWAB, LEENDERT WILLEM; BERTLEFF, MARIËTTA JOHANNA OLGA ELIZABETH; DE VRIES, HARMEN HENDRIKUS
To: POLYGANICS IP B.V.
Reel/Frame 044506/0340 →
Priority Claims (1)
NL 2014410 · Mar 6, 2015 · national
Continuity (1)
Related Publication 20180339083A1 · Nov 29, 2018